FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Guide on Technical Specs for NASH Drug Data Sets

FDA posts a revised guidance entitled Technical Specifications for Submitting Clinical Trial Data Sets for Treatment of Noncirrhotic Nonalcoholic Stea...

Medical Devices

Medtronic Recalls HawkOne Atherectomy System

Medtronic recalls its HawkOne Directional Atherectomy System due to the risk of the guidewire within the catheter moving downward or prolapsing when f...

Human Drugs

FDA Lifts Hold on Kura Leukemia Trial

FDA lifts a partial clinical hold on a Kura Oncology Phase 1b study (KOMET-001) of KO-539 in patients with relapsed or refractory acute myeloid leukem...

Human Drugs

Pazdur Mulls Accelerated Approval International Harmonization

FDA Oncology Center of Excellence director Richard Pazdur suggests changes to the agencys accelerated approval program, such as international harmoniz...

Human Drugs

Arch Oncology Orphan Status for Multiple Myeloma

FDA grants Arch Oncology an orphan drug designation for AO-176 and its use in treating relapsed/refractory multiple myeloma.

Human Drugs

Pfizer/OPKO Complete Response on Growth Hormone

FDA issues Pfizer and OPKO Health a complete response letter for their BLA for somatrogon, an investigational once-weekly long-acting recombinant huma...

Federal Register

Proposal to Classify Certain Antigen Devices in Class 2

Federal Register notice: FDA seeks comments on its proposal to classify human leukocyte antigen, human platelet antigen, and human neutrophil antigen ...

Federal Register

Class 2 for Retinal Diagnostic Software Devices

Federal Register notice: FDA classifies retinal diagnostic software devices into Class 2 (special controls).

Human Drugs

Improve Accelerated Approval Process: Califf

FDA commissioner nominee Robert Califf says ways must be found to speed confirmatory trials for drugs given accelerated approval.

Human Drugs

FDA Hold on Dyne Muscular Dystrophy IND

FDA places a clinical hold on Dyne Therapeutics IND for a trial of Dyne-251 to treat Duchenne muscular dystrophy.